1. Volume 6, Issue 2, Pages e116-e127 (February 2019)
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study 
Prof Andrew N Phillips, PhD, Prof Francois Venter, FCP[SA], Prof Diane Havlir, PhD, Prof Anton Pozniak, PhD, Prof Daniel Kuritzkes, MD, Prof Annemarie Wensing, PhD, Prof Jens D Lundgren, DMSc, Prof Andrea De Luca, PhD, Prof Deenan Pillay, PhD, Prof John Mellors, MD, Valentina Cambiano, PhD, Loveleen Bansi-Matharu, PhD, Fumiyo Nakagawa, PhD, Thokozani Kalua, MBBS, Andreas Jahn, PhD, Tsitsi Apollo, PhD, Owen Mugurungi, PhD, Polly Clayden, Prof Ravindra K Gupta, PhD, Ruanne Barnabas, PhD, Paul Revill, MSc, Jennifer Cohn, PhD, Silvia Bertagnolio, PhD, Prof Alexandra Calmy, PhD 
The Lancet HIV 
Volume 6, Issue 2, Pages e116-e127 (February 2019)
DOI: /S (18)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure
Overall health benefit (DALYs averted) and increment in cost compared with tenofovir, lamivudine, and efavirenz for all
Values are the mean over 3 month periods of 1000 setting scenarios during 20 year time periods, expressed per year. DALY=disability adjusted life-year.
The Lancet HIV 2019 6, e116-e127DOI: ( /S (18) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions